Hebrew
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

triple negative breast neoplasms/אלבומין

הקישור נשמר בלוח
13 תוצאות

SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer

רק משתמשים רשומים יכולים לתרגם מאמרים
התחבר הרשם

A Proof of Concept Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast Cancer

רק משתמשים רשומים יכולים לתרגם מאמרים
התחבר הרשם
TNBC is an aggressive subtype of breast cancer associated with poor survival and new treatments are needed. A key feature of cancer is its ability to go undetected by the immune system. Recent developments in cancer research have identified immune checkpoints as a possible treatment option as they

Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer

רק משתמשים רשומים יכולים לתרגם מאמרים
התחבר הרשם
Triple-negative breast cancer is named because of lack of expression of estrogen receptor, progesterone receptor, and proto-oncogene HER2. This type of breast cancer is highly heterogeneous, is more likely to recur locally and develop distant metastasis, and has high invasiveness and low survival

Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective RCT

רק משתמשים רשומים יכולים לתרגם מאמרים
התחבר הרשם
Breast cancer has been one of the most common malignant tumors with highest morbidity and mortality that threatens women's health worldwide. Among US women, there were 250,000 new invasive breast cancers and 40,000 breast cancer deaths in 2017. In the US, 12.4% women develop breast cancer in their

CTC Changes and Efficacy of Neoadjuvant Chemotherapy for Triple-negative Breast Cancer

רק משתמשים רשומים יכולים לתרגם מאמרים
התחבר הרשם
Triple-negative breast cancer refers to breast cancer with negative human epidermal growth factor receptor 2, estrogen receptor and progesterone receptor. Triple-negative breast cancer has poor differentiation, high invasiveness and high recurrence rate, accounting for 15.0%-23.8% of breast cancer.

Albumin-Bound Paclitaxel Followed by Epirubicin in Combination With Cyclophosphamide in Triple Negative Breast Cancer

רק משתמשים רשומים יכולים לתרגם מאמרים
התחבר הרשם

A Proof of Concept, Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast Cancer

רק משתמשים רשומים יכולים לתרגם מאמרים
התחבר הרשם
TNBC is an aggressive subtype of breast cancer associated with poor survival and new treatments are needed. A key feature of cancer is its ability to go undetected by the immune system. Recent developments in cancer research have identified immune checkpoints as a possible treatment option as they
In the dose escalation phase, the following will be assessed: - Arm A: escalating doses of AB928 in combination with PLD at standard doses will be assessed in participants with advanced metastatic triple-negative breast cancer or ovarian cancer. Eligible participants will receive oral administration
Neoadjuvant program: apatinib 250mg oral d1-21; albumin paclitaxel 260mg/m2 intravenous drip d1; carboplatin AUC=5-6 intravenous drip d1; 21 days for 1 cycle. The treatment regimen was used for a total of 6 cycles, or to PD, or the toxicity was not tolerated. If there is still no PD after 6 cycles,

Pilot Study To Investigate Targetable Metabolic Pathways Sustaining Triple Negative Breast Cancer

רק משתמשים רשומים יכולים לתרגם מאמרים
התחבר הרשם
One of the recognized hallmarks of cancer cells is deregulated cellular metabolism, characterized by enhanced metabolic autonomy compare with non-transformed cells. Tumor cells typically display an overall increase in glucose metabolism, associated with enhanced aerobic glycolysis and decreased

IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer

רק משתמשים רשומים יכולים לתרגם מאמרים
התחבר הרשם
The prognosis and survival rate of breast cancer varies depending on the extent of the disease, performance status of patients and the type of tumour including the status of oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2). Expression of ER and
PRIMARY OBJECTIVES: I. To test the hypothesis that carboplatin + nab-paclitaxel (paclitaxel albumin-stabilized nanoparticle formulation) therapy will demonstrate a promising neoadjuvant pathologic complete response (pCR) rate for eligible patients. II. To test the hypothesis that carboplatin +
הצטרפו לדף הפייסבוק שלנו

המאגר השלם ביותר של צמחי מרפא המגובה על ידי המדע

  • עובד ב 55 שפות
  • מרפא צמחי מרפא מגובה על ידי מדע
  • זיהוי עשבי תיבול על ידי דימוי
  • מפת GPS אינטראקטיבית - תייגו עשבי תיבול במיקום (בקרוב)
  • קרא פרסומים מדעיים הקשורים לחיפוש שלך
  • חפש עשבי מרפא על פי השפעותיהם
  • ארגן את תחומי העניין שלך והתעדכן במחקר החדשות, הניסויים הקליניים והפטנטים

הקלד סימפטום או מחלה וקרא על צמחי מרפא שעשויים לעזור, הקלד עשב וראה מחלות ותסמינים שהוא משמש נגד.
* כל המידע מבוסס על מחקר מדעי שפורסם

Google Play badgeApp Store badge